Logo

Incyte and MorphoSys Report First Patient Dosing in P-III frontMIND Study of Tafasitamab + Lenalidomide as a 1L Treatment for DLBCL

Share this

Incyte and MorphoSys Report First Patient Dosing in P-III frontMIND Study of Tafasitamab + Lenalidomide as a 1L Treatment for DLBCL

Shots:

  • The first patient has been dosed in the P-III frontMIND study evaluating tafasitamab + lenalidomide + R-CHOP vs R-CHOP alone as a 1L treatment for high-intermediate and high-risk ~880 patients with DLBCL
  • The 1EP of the study is PFS and 2EP include event-free survival- OS- metabolic CRR- and ORR
  • The preliminary data from the ongoing P-Ib firstMIND study showed a 91.1% response rate across both arms in a patient population- and combination therapy showed a tolerable profile. The results will further support the frontMIND study for the combination therapy

  Ref: Business Wire | Image: Business Wire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions